Direct answer
Vitamin D supports calcium absorption and bone health; correcting deficiency helps prevent rickets and osteomalacia. D3 generally raises blood levels more than D2. Routine supplements have not reliably prevented cancer, cardiovascular events, depression or fractures in mostly replete adults, while selected high-risk prediabetes has a conditional recommendation alongside lifestyle. Calcifediol, active vitamin D and experimental delivery forms need distinct assessment. The adult chronic total-intake upper limit is 4,000 IU/day, not a target; high doses, calcium-related conditions and interacting medicines require individual care. Pharmaceutical funding, product donations and remaining financial gaps are disclosed.
- D3 usually raises blood 25(OH)D more effectively than D2. Tripkovic’s 2012 review included 10 studies qualitatively and 7 in the pooled analysis; its D3 advantage was clearest with bolus dosing, while daily-dose differences were not significant (Tripkovic meta-analysis). (Tripkovic 2012 review)
- Correcting vitamin D deficiency supports bone and mineral health. In mostly replete older adults, VITAL did not reduce invasive cancer or major cardiovascular events; fracture reviews do not support routine supplementation in healthy community adults. A result below 20 ng/mL is not a universal treatment threshold (NIH ODS; VITAL; USPSTF review).
- People with limited sun exposure, malabsorption, older age or other deficiency risks may need an individualized assessment of vitamin D intake and status; risk factors do not mean every person benefits from routine testing. (Mayo Clinic vitamin D guidance)
- Adult recommended total intake is 600–800 IU/day depending on age. Deficiency treatment dose and retesting depend on clinical context; the adult upper limit for chronic total intake is 4,000 IU/day. (National Academies UL chapter; Mayo Clinic vitamin D guidance)
- Drug interactions include increased calcium risk with thiazides or digoxin and altered vitamin D status with some anticonvulsants, steroids or fat-absorption medicines. The exact risk and monitoring depend on the medicine (Mayo Clinic). (Mayo Clinic vitamin D guidance)
- Evidence grade: Moderate
Vitamin D supports calcium absorption and bone mineralization; correcting deficiency helps prevent rickets and osteomalacia. Routine supplementation in mostly replete adults has not reliably prevented invasive cancer, major cardiovascular events, depression or fractures (NIH Office of Dietary Supplements, VITAL trial, USPSTF evidence review). A separate 2024 guideline conditionally suggests vitamin D alongside lifestyle changes for selected people with high-risk prediabetes (Endocrine Society guideline). D3 generally raises blood 25(OH)D better than D2; calcifediol raises it faster in studied regimens but has pharmaceutical funding and has not established superior fracture prevention (D2/D3 meta-analysis, calcifediol trial). The adult upper limit is 4,000 IU/day from total intake, a chronic population reference rather than a treatment dose. Excess vitamin D can cause high calcium and kidney injury; medicines and conditions that affect calcium require individual assessment (NIH ODS, National Academies UL chapter).
Table of Contents
- Evidence summary
- What vitamin D is
- Forms and delivery options
- How vitamin D works
- What works and what does not
- Benefits with evidence grades
- Risks and side effects
- Medicine and supplement interactions
- Who should avoid vitamin D
- Dosage and how to take it
- Independent research, funding, and conflict review
- Frequently asked questions
- Sources
Evidence summary
| Claim | Evidence | Source country | Funding / conflict check | Strength |
|---|---|---|---|---|
| D3 generally raises 25(OH)D more than D2, especially with bolus dosing. | Ten studies qualitatively and seven pooled; daily-dose difference was not significant. | United Kingdom | BBSRC DRINC grant BB/I006192/1; programme cofinanced by public funds and food/drink industry. No COI declared in the review (UKRI programme funding). | Moderate; status marker Original review |
| Calcifediol raised 25(OH)D faster in the tested monthly regimens. | Postmenopausal women with baseline <20 ng/mL: monthly calcifediol 0.266 mg versus D3 25,000 IU; 35.0% versus 8.2% reached >30 by month four. Clinical fracture superiority was not tested. | Spain / Italy | Faes Farma and Bruno Farmaceutici funding; four Faes employees and other author consultancy/research/lecture ties. | Moderate; status marker Original trial |
| Routine vitamin D did not show a fracture reduction in the reviewed healthy community adults. | Eleven RCTs in adults without known deficiency, osteoporosis or prior fracture; review rated fracture conclusions low certainty. | United States | AHRQ-funded evidence review; LeBlanc reported unrelated institutional pharmaceutical research support. | Low for no fracture benefit Original review |
| Vitamin D plus calcium modestly reduced hip fractures in older adults; harms require separate interpretation. | Hip RR 0.84: about one fewer per 1,000 community adults per year versus nine fewer in institutions. Hypercalcemia RR 2.28 pools vitamin D or analogues, with or without calcium; it is not a D+Ca-specific estimate. | United Kingdom / international trials | Current review funding/COI not verified from its public summary; underlying-trial independence remains unknown. | Strong for small hip benefit Cochrane summary |
| Vitamin D3 2,000 IU/day did not reduce primary invasive-cancer or major-CV endpoints in VITAL. | 25,871 older adults, median 5.3 years: cancer HR 0.96; major cardiovascular events HR 0.97. | United States | NIH-funded; Pharmavite/Pronova/BASF donated products and packaging, and Quest supplied assays. A VITAL report also discloses Buring’s spouse on Pharmavite’s advisory board (original financial disclosures). | Strong for these trial endpoints VITAL / Original full text |
| Vitamin D3 2,000 IU/day did not reduce depression outcomes in VITAL-DEP. | 18,353 middle-aged/older adults; depression HR 0.97, without a mood-score benefit. | United States | NIH grants plus donated agents/placebos/packaging and free Quest assays; author financial relationships include Buring’s spouse on Pharmavite’s advisory board. | Strong for broad prevention in this cohort VITAL-DEP |
| Vitamin D has not shown clear overall protection against acute respiratory infections in the updated evidence. (2017 BMJ review; 2025 ARI update) | A 2025 update found no statistically significant overall protection; earlier deficiency subgroup estimates were not confirmed. (2025 ARI update) | United Kingdom / international trials | 2017 review: NIHR-funded, no relevant financial ties declared. 2025 review: no external study funding; several authors disclosed outside supplement/pharma ties. (2017 BMJ review; 2025 ARI update) | Weak for a prevention claim |
| D2d’s individual trial was negative; current high-risk-prediabetes guidance is conditional. | D2d HR 0.88 (95% CI 0.75–1.04), P=0.12. The 2024 guideline suggests supplementation alongside lifestyle for selected high-risk prediabetes. | United States | NIDDK/NIH ODS primary and ADA secondary support; trial capsules purchased from an unrelated supplement company. Separate individual disclosure forms were not fully reviewed. | Trial null; conditional guideline D2d; 2024 guideline |
| Vitamin D is not established as routine COVID-19 treatment by these reviews. | The 2021 treatment review excluded prevention studies and found very uncertain effects. The 2025 deficient-patient meta-analysis had a non-robust mortality signal and no clear ICU/ventilation benefit. | Germany / China | 2021: Cologne institutional and German BMBF CEOsys support. 2025: Hunan public education/health and university programme grants; no COI declared. Included-trial finances not all traced. | Uncertain clinical benefit 2021 treatment review; 2025 review |
What vitamin D is
Vitamin D is a fat-soluble prohormone, not just a simple vitamin: skin makes vitamin D3 after UVB exposure, foods and supplements provide D2 or D3, the liver converts them to 25-hydroxyvitamin D [25(OH)D or calcifediol], and the kidney and other tissues convert 25(OH)D to the active hormone 1,25-dihydroxyvitamin D [1,25(OH)2D or calcitriol] (NIH Office of Dietary Supplements). The 25(OH)D blood test is the usual status marker because it reflects vitamin D from sun, food, and supplements, while calcitriol can be normal or high even when stores are low (NIH Office of Dietary Supplements).
The active compounds — what actually does the work
D2 and D3 are storage-input forms; calcifediol is the circulating status form; calcitriol is the active hormone that binds the vitamin D receptor and regulates calcium/phosphorus homeostasis, bone mineralization, and many gene-expression pathways (NIH Office of Dietary Supplements). This distinction matters because a D3 capsule, a calcifediol softgel, and prescription calcitriol are not interchangeable: D3 is typical nutritional replacement, calcifediol is faster and more predictable in some malabsorption or liver-conversion contexts, and calcitriol is a prescription active hormone with higher hypercalcemia risk (Calcifediol review, Cochrane mortality review).
Forms and delivery options
| Form / delivery | What it is | Bioavailability / potency | Best use | Cost / access | Verdict |
|---|---|---|---|---|---|
| D3 / cholecalciferol | Animal- or lichen-derived; oral capsules, tablets, drops and fortified foods are nutritional options. | Generally raises 25(OH)D more than D2. A daily 15 µg winter trial in South Asian and White European women also favoured D3, although the earlier pooled daily comparison was nonsignificant (2012 review, daily trial). | A practical form when supplementation is indicated. | Price varies by product, dose and pack size. | Practical nutritional option |
| D2 / ergocalciferol | Plant/fungal vitamin D used in supplements and fortification. | Raises vitamin D status; a healthy-volunteer trial found higher 25(OH)D2 but lower measured 25(OH)D3 during D2 use (D2/D3 trial). | An effective nutritional option; suitability depends on the product and clinical plan. | Prices vary by dose and product. | Effective; status response may differ |
| Calcifediol / 25(OH)D3 | Pre-hydroxylated metabolite measured as part of 25(OH)D status. | Faster marker response in selected regimens. A narrative review cites absorption estimates of 93% versus 79% for D3; these are not universal comparative constants (calcifediol review, monthly trial). | Clinician-directed use in selected correction, absorption or liver-conversion contexts; not proven superior fracture prevention. | Availability and prescription status vary; trial evidence includes pharmaceutical conflicts. | Clinician-directed option |
| Calcitriol / 1,25(OH)2D | Active vitamin D hormone; prescription drug. | Bypasses activation steps and can cause hypercalcemia (toxicity review). | Selected kidney/mineral or hypoparathyroid conditions under specialist care. | Prescription medicine; not interchangeable with D3. | Medical supervision |
| Liposomal D3 | D3 in lipid vesicles intended to alter delivery. | A healthy-adult crossover experiment used one fasted 10,000-IU dose and measured early five-hour marker changes. Two authors were Lipid Systems partners and two employees (original experiment). | No established indication for failed ordinary D3 or malabsorption follows from this experiment. | Clinical benefit and cost advantage over standard D3 were not established. | Exploratory; commercial ties |
| D3 + K2 combination | Vitamin D combined with vitamin K, often retail K2/MK-7. | An eight-trial meta-analysis reported BMD and osteocalcin-marker changes; its abstract does not establish fewer fractures or cardiovascular events (K+D meta-analysis). | Routine added K2 is not established as necessary for everyone taking D3. | Price depends on ingredients, dose and pack size. | Routine clinical benefit unestablished |
| Capsules / softgels / tablets | Oral vitamin D delivery forms. | Fat can aid absorption; fat-malabsorption medicines and disorders may affect uptake (NIH ODS, interaction review). | Dose and schedule depend on indication; lower daily dosing is preferred to nondaily high dosing for adults ≥50 with a treatment indication (2024 guideline). | Prices vary by dose, formulation and product. | Practical option |
| Drops / sprays | Liquid or spray delivery; infant products require age-appropriate dosing. | Liquid dose must be measured accurately; concentrated-product errors can cause overdose (toxicity review). | Liquid drops can help people who cannot take tablets; the infant prevention dose is 400 IU/day (NIH ODS). | Price varies; check concentration and the measuring device. | Measure carefully |
| Injections / high-dose sachets | Medical high-dose preparations and schedules, distinct from ordinary maintenance. | The 2014 India review describes historical oral Indian regimens; its intramuscular example is from Pakistan. It is not current Indian injection guidance (original review). Older-adult reviews raise concerns about large intermittent dosing (fracture meta-analysis). | Any high-dose or injected treatment needs an individual clinical indication. | Product, dose and prescription determine access and cost. | Avoid unsupervised megadoses |
Read the practical summary
| Form | Source | Effect | Best use | Verdict |
|---|---|---|---|---|
| D2 / ergocalciferol | Plant- or fungal-derived vitamin D. | Raises 25(OH)D; D3 generally produces a larger status response (D2/D3 review). | Fortification or supplementation when suitable. | Effective nutritional option. |
| D3 / cholecalciferol | Made in skin; nutritional products may use animal or lichen sources. | Generally produces a larger 25(OH)D response than D2; a later daily trial also favoured D3 (review, daily trial). | Supplementation when indicated. | Status-marker advantage; clinical needs vary. |
How it works
What the body does with it
Vitamin D improves intestinal absorption of calcium and phosphorus, which is why inadequate vitamin D can impair bone mineralization and cause rickets in children or osteomalacia in adults (NIH Office of Dietary Supplements). The National Academies committee emphasized that vitamin D requirements assume adequate calcium intake and that “no amount of vitamin D is able to compensate for inadequate total calcium intake” (National Academies DRI report).
Why form and delivery matter
Dietary fat can aid D2/D3 absorption, and both need hepatic processing. Calcifediol skips 25-hydroxylation and may give a faster, more predictable status response in selected clinical contexts; calcitriol bypasses both activation steps and carries more calcium-related risk (calcifediol review). Orlistat, cholestyramine and fat-malabsorption disorders can affect nutritional vitamin D absorption (interaction review; Mayo Clinic).
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Bone health / deficiency diseases | WORKS | Vitamin D is essential for calcium absorption and prevention/treatment of rickets and osteomalacia (NIH Office of Dietary Supplements). | Requires adequate calcium; benefits are clearest in deficient people. |
| Fracture prevention in generally healthy community adults | NO CLEAR REDUCTION IN THESE TRIALS | The review found no association with lower fracture incidence in adults without known deficiency or osteoporosis, rating these conclusions low certainty (USPSTF evidence review). | Does not apply to diagnosed deficiency, osteoporosis or institutionalized frail adults. |
| Fracture prevention in high-risk older adults | MIXED | Cochrane found vitamin D alone unlikely to prevent fractures, while vitamin D plus calcium produced a small hip-fracture reduction, especially in institutionalized older adults (Cochrane). | Calcium co-use raises kidney stone/renal and GI adverse-event concerns. |
| Mood / depression prevention | DOESN'T | VITAL-DEP found no significant reduction in depression or clinically relevant depressive symptoms with 2,000 IU/day D3 (VITAL-DEP). | Treat deficiency if present, but do not market D3 as an antidepressant. |
| Immune support / acute respiratory infections | UNCERTAIN | The 2025 update found no significant overall protection; a daily-dose subgroup signal did not establish a reliable subgroup effect (2025 ARI update). | Correct deficiency for bone health; do not promise infection prevention. |
| Cancer prevention | DOESN'T | VITAL found 2,000 IU/day D3 did not lower invasive cancer incidence (VITAL). | Cancer mortality signals remain hypothesis-generating, not a prevention claim. |
| Cardiovascular prevention | DOESN'T | VITAL found no reduction in major cardiovascular events (VITAL). | Observational low-D associations do not prove supplements prevent heart disease. |
| Diabetes prevention | SELECTED HIGH-RISK USE | D2d alone was nonsignificant, HR 0.88 (0.75–1.04) (D2d). A 2024 guideline conditionally suggests vitamin D alongside lifestyle for high-risk prediabetes (current guideline). | This is not a recommendation for general-population prevention, established-diabetes treatment or self-prescribing 4,000 IU/day. |
| Mortality | MIXED | The 2014 Cochrane review estimated one fewer death per 150 people treated over five years, mainly in older populations; substantial attrition and outcome-reporting bias limited confidence (mortality review). | The estimate used trials searched through February 2012, included industry-supported trials and does not prove longevity benefits for every healthy adult. |
| Muscle strength / falls | MIXED | Severe deficiency can cause weakness, but high intermittent dosing in older healthy populations may not help and may increase fracture/fall concerns (elderly fracture meta-analysis, NIH Office of Dietary Supplements). | Avoid large boluses unless prescribed. |
| COVID-19 treatment | INSUFFICIENT EVIDENCE | The 2021 treatment review, which excluded prevention trials, found very uncertain effects; the 2025 deficient-patient review found a non-robust mortality signal and no clear ICU/ventilation benefit (Cochrane treatment review, 2025 review). | Neither review establishes routine COVID treatment or prevention; deficiency care is a separate indication. |
Read the practical summary
- Works: deficiency correction, rickets/osteomalacia prevention, calcium absorption.
- Mixed: fracture prevention in high-risk institutionalized older adults when paired with calcium, and mortality. Respiratory-infection prevention remains uncertain.
- Not supported for routine prevention: invasive cancer, major cardiovascular events and depression in the large older-adult trials discussed here. Selected high-risk prediabetes is a separate conditional indication alongside lifestyle (2024 guideline).
- Insufficient: these treatment reviews do not establish routine COVID-19 treatment and did not test prevention.
- Practical rule: correcting deficiency supports bone and mineral health. Other prevention decisions depend on the studied population and endpoint; a low blood level does not prove benefit for every disease (NIH ODS; 2024 guideline).
Benefits by claim
Bone and mineral metabolism — Strong for deficiency correction; mixed for fractures
Vitamin D’s clearest benefit is preventing and treating deficiency states that impair calcium absorption and bone mineralization (NIH ODS). Vitamin D alone was unlikely to prevent fractures in the reviewed older-adult trials. Added calcium produced a small hip-fracture reduction, with larger absolute benefit in institutions; GI and renal harms need consideration. The review’s pooled hypercalcemia estimate also includes active analogues and must not be assigned solely to ordinary D3 plus calcium (Cochrane summary).
Mood and depression — Strong evidence against broad prevention
The best large trial does not support vitamin D as a depression-prevention supplement: VITAL-DEP found no significant difference in depression incidence or mood-score change with 2,000 IU/day D3 compared with placebo (VITAL-DEP). A low vitamin D result can coexist with depression because illness, indoor lifestyle, obesity, inflammation, or low activity can reduce vitamin D status; that association does not prove that D3 treats depression.
Immune and respiratory infections — Weak evidence for a prevention claim
The 2017 individual-participant review reported modest protection, especially in profound deficiency without bolus dosing (BMJ). The larger 2025 update found no statistically significant overall protection and did not confirm the deficient subgroup benefit. Daily dosing showed a subgroup signal, but formal interaction tests did not establish which groups benefit (2025 ARI update).
Cancer and cardiovascular prevention; selected high-risk prediabetes
VITAL found no significant reduction in invasive cancer or major cardiovascular events with 2,000 IU/day D3 in 25,871 older adults over median 5.3 years (VITAL). D2d individually found no significant diabetes-prevention benefit from 4,000 IU/day in high-risk prediabetes not selected for vitamin D deficiency (D2d). Considering the wider trial evidence, the 2024 Endocrine Society guideline conditionally suggests vitamin D in addition to lifestyle changes for selected high-risk prediabetes, without identifying one recommended dose (2024 guideline).
Mortality — Older evidence with important limitations
The 2014 Cochrane review reported a small mortality reduction with D3, corresponding to roughly 150 people treated over five years to prevent one death. Most participants were older women, and substantial missing follow-up and outcome-reporting bias limited confidence. Dose and baseline-status subgroup differences were not confirmed; the review is not proof that high-dose D3 extends life in healthy people (original mortality review). Higher serum levels have been associated with harm in observational evidence, which does not establish that supplements caused those outcomes (NIH ODS).
Risks and side effects
Vitamin D toxicity is primarily a calcium problem: excessive vitamin D can cause hypercalcemia, hypercalciuria, kidney stones, soft-tissue/vascular calcification, kidney injury, nausea, vomiting, constipation, weakness, confusion, dehydration, excessive thirst, and abnormal heart rhythm risk (NIH Office of Dietary Supplements, Vitamin D Toxicity clinical review). The National Academies adult upper limit is 100 mcg/day, equal to 4,000 IU/day, for adults and children 9 years and older (NIH Office of Dietary Supplements, IOM/NAM UL chapter). The UL is a chronic total-intake reference, not an intake target; clinician-directed treatment and monitored research require separate assessment.
| Side effect / risk | Frequency | Dose relationship | What to watch for | Evidence |
|---|---|---|---|---|
| Hypercalcemia | Frequency varies by regimen and condition; standard-dose incidence is not quantified here. | Excess doses, active forms, granulomatous disease, kidney/mineral disorders and thiazide/calcium co-use require particular care. | Nausea, vomiting, weakness, confusion, thirst, urination and arrhythmia risk. | Nutritional D2/D3 overdose typically involves 25(OH)D >150 ng/mL, but active-form or endogenous excess can cause hypercalcemia with normal or low 25(OH)D (NIH ODS, toxicity review). |
| Kidney stones / renal events | Measurable excess stone events occurred in large trials with calcium co-use. | Calcium plus D increased stones versus control in some trials; the effect of D alone was uncertain. | Flank pain, blood in urine, recurrent stones or high urine calcium. | WHI calcium plus D increased stone risk by 17%; the USPSTF pooled absolute increase was 0.33% (NIH ODS; USPSTF evidence review). |
| Nausea, constipation, weakness | These can occur with hypercalcemia; incidence at ordinary doses is not established by this source. | Risk depends on dose, calcium co-use, active forms and medical context. | Seek clinical assessment for symptoms during supplementation, especially with high doses or calcium-affecting medicines. | Recognized toxicity manifestations; not a quantified low-dose adverse-event rate (NIH ODS). |
| Toxicity from high doses | Described as rare in the clinical review, but prevalence is unknown. | Excess supplements, prescription errors, concentrated liquids and stacked products can cause toxicity; 4,000 IU/day is the adult chronic UL, not a target. | High calcium, kidney injury and neurological/GI symptoms; serum 25(OH)D depends on the cause. | >150 ng/mL is characteristic of nutritional D2/D3 overdose, not a safety threshold that excludes other forms of hypercalcemia (toxicity review). |
| U-shaped mortality curve debate | Observational association, not a proven supplement side effect. | Possible risk signal at high serum levels; interpretation is debated because illness, testing behavior, and supplementation patterns can confound results. | Avoid chasing high-normal or supraphysiologic 25(OH)D without medical reason. | NIH summarizes National Academies concern about avoiding serum 25(OH)D above roughly 50–60 ng/mL and notes associations above 30–48 ng/mL in some outcomes (NIH ODS). |
| High intermittent bolus risk | Regimen and population matter. | Some large-dose older-adult trials raised fall/fracture concerns; this is not proof every intermittent schedule is harmful. | Avoid self-prescribed monthly/annual megadoses. | For adults ≥50 with an indication, the 2024 guideline suggests lower daily over nondaily high dosing, with low-certainty evidence (guideline). The 2025 ARI update does not establish reliable infection prevention. |
Read the practical summary
Low vitamin D can impair bone and mineral health; excessive supplementation can cause hypercalcemia and injury. The adult chronic total-intake UL is 4,000 IU/day. A 25(OH)D level >150 ng/mL is typical of nutritional D2/D3 overdose, while active-form or endogenous excess can cause hypercalcemia at lower levels (toxicity review). The UL is a reference ceiling, not a wellness target (National Academies).
Medicine and supplement interactions
| Interacts with | Type | Severity | Mechanism | Action |
|---|---|---|---|---|
| Corticosteroids — prednisone, dexamethasone, long-term steroid therapy | Bone/mineral and possible vitamin D effects | Clinical assessment | Steroids can affect calcium absorption and vitamin D metabolism, but the interaction review found inconsistent clinical 25(OH)D results (systematic review, Mayo Clinic). | Assess bone risk, calcium intake and monitoring with the prescriber; vitamin D alone is not a complete steroid bone-protection plan. |
| Weight-loss drugs — orlistat / Xenical / Alli | Reduced fat-soluble-vitamin absorption | Follow medicine instructions | Orlistat can reduce vitamin D uptake (NIH ODS, Mayo Clinic). | Follow the exact orlistat product’s instructions for vitamin timing and discuss monitoring if needed. |
| Bile acid sequestrants — cholestyramine, colestipol, colesevelam | Reduced absorption | Separate timing | These bind bile acids and reduce micelle formation needed for absorption of fat-soluble vitamins; Mayo specifically lists cholestyramine lowering vitamin D uptake (Mayo Clinic). | Follow the exact medicine’s instructions for timing vitamin supplements; intervals differ by sequestrant. Monitor 25(OH)D if used chronically. |
| Anticonvulsants — phenytoin, phenobarbital and related medicines | Possible vitamin D/bone effects | Clinical assessment | Enzyme induction can affect vitamin D metabolism; Mayo lists phenytoin/phenobarbital, while the systematic review found insufficient consistent evidence for predicting 25(OH)D changes (review, Mayo Clinic). | Discuss bone health and any indicated vitamin D testing or dosing with the prescriber. |
| Tuberculosis medicines — rifampin, isoniazid | Metabolism alteration | Monitor | Rifampin induces CYP3A4 and isoniazid inhibits CYP3A4; small time-series studies reported mixed 25(OH)D effects, so systematic review recommends monitoring rather than assuming a predictable effect (drug-vitamin D systematic review). | Monitor 25(OH)D and calcium during prolonged TB therapy; avoid high-dose D in granulomatous disease unless supervised. |
| Thiazide diuretics — hydrochlorothiazide, chlorthalidone, indapamide | Hypercalcemia risk | Use caution / monitor calcium | Thiazides decrease urinary calcium excretion while vitamin D increases calcium absorption, which can cause or worsen hypercalcemia (drug-vitamin D systematic review, Mayo Clinic). | Do not combine high-dose D/calcium with thiazides without checking serum calcium, especially in older adults, kidney disease, or hyperparathyroidism. |
| Calcium supplements — calcium carbonate, citrate, high-calcium antacids | Additive calcium load | Monitor | Vitamin D increases calcium absorption; combined calcium+D increased kidney stones in large evidence reviews (NIH ODS, USPSTF evidence review). | Use calcium only when diet is inadequate or prescribed; avoid exceeding total calcium needs. |
| Digoxin — Lanoxin | Hypercalcemia amplifies toxicity | Avoid high-dose D | High-dose vitamin D can cause hypercalcemia, and hypercalcemia increases risk of fatal heart rhythm problems with digoxin (Mayo Clinic). | Avoid high-dose vitamin D unless the prescriber is monitoring calcium and digoxin risk. |
| Aluminum-containing antacids / phosphate binders | Aluminum toxicity risk | Use caution / avoid in kidney failure | Vitamin D with aluminum-containing phosphate binders may cause harmful aluminum levels in people with kidney failure (Mayo Clinic). | Avoid chronic co-use in kidney disease unless prescribed and monitored. |
| Vitamin K antagonists — warfarin, acenocoumarol; relevant to D3+K2 | Vitamin K can alter anticoagulation | Avoid unsupervised K2 | Abrupt changes in vitamin K from food or supplements can alter anticoagulation (NIH vitamin K guidance). The cited model used 20–70 mg intravenous K2; it does not quantify retail oral MK-7 effects (IV K2 model). | Keep vitamin K intake consistent and do not start D3+K2 without the anticoagulation clinician’s advice. |
Who should avoid vitamin D or use it only medically
Seek individual clinical advice before vitamin D, especially high-dose products, if you have high calcium, recurrent stones, advanced kidney disease, hyperparathyroidism, sarcoidosis or other granulomatous disease, lymphoma, or use active vitamin D, thiazides, digoxin or high-dose calcium (NIH ODS, toxicity review). Anticonvulsants, steroids, tuberculosis medicines and fat-malabsorption medicines can affect bone/mineral care or vitamin D handling; clinical 25(OH)D effects vary and monitoring depends on the medicine (interaction review).
Dosage and how to take it
The National Academies recommended total intake is 600 IU/day for adults through age 70 and 800 IU/day thereafter; the adult chronic UL is 4,000 IU/day (NIH ODS). ESCEO’s historical 2013 advice suggested 800–1,000 IU/day below 20 ng/mL in older/postmenopausal bone-health contexts; the meeting was supported by ESCEO and authors disclosed extensive pharmaceutical/food ties (original ESCEO recommendations). Current prevention guidance does not endorse a universal 25(OH)D treatment target or routine testing of healthy adults. Established deficiency or mineral disease needs separate clinical management (2024 guideline).
| 25(OH)D result if clinically tested | FNB population interpretation | Clinical context | Notes |
|---|---|---|---|
| <12 ng/mL / <30 nmol/L | Risk of deficiency (FNB interpretation) | Medical assessment of symptoms, calcium/mineral health, diet and underlying causes; treatment and retesting depend on diagnosis. | FNB nutritional interpretation, not a universal disease-prevention target. |
| 12–20 ng/mL / 30–50 nmol/L | Potential inadequacy for some people (FNB interpretation) | Assess intake and clinical context; this result alone does not prescribe 800–2,000 IU/day, weekly treatment or routine retesting. | For adults ≥50 with an indication, current guidance favours lower daily over nondaily high dosing (2024 guideline). |
| 20–30 ng/mL / 50–75 nmol/L | Adequate for most people under FNB nutritional criteria (NIH ODS) | Meet recommended intake through food, fortified foods and supplements if needed. | Clinical disease-specific assessment may differ; extra UV exposure is not required or risk-free. |
| 30–50 ng/mL / 75–125 nmol/L | A higher result is not proven better | Avoid escalating doses merely to chase a higher number. | No universal disease-prevention target; FNB advises avoiding levels above roughly 50–60 ng/mL (NIH ODS). |
| >50–60 ng/mL / >125–150 nmol/L | Potentially excessive depending on context | Review supplements and calcium; consider clinician assessment. | Risk is higher with symptoms, high calcium, kidney disease, thiazides, or active vitamin D. |
A meal containing fat can aid D3 absorption. Follow medicine-specific instructions for orlistat or bile-acid sequestrants, and count all supplements, fortified products and medical doses (NIH ODS, Mayo Clinic). Do not add K2 to a warfarin regimen without anticoagulation advice; maintain consistent vitamin K intake (NIH vitamin K guidance).
Read the practical summary
| 25(OH)D result | Action |
|---|---|
| <12 ng/mL | Assess possible deficiency and underlying cause with a clinician; treatment depends on diagnosis (NIH ODS). |
| 12–20 ng/mL | Potential inadequacy; assess intake and context rather than automatically prescribing a dose or repeat tests (FNB interpretation; 2024 guidance). |
| 20–50 ng/mL | Meet recommended intake; higher levels or extra sunlight do not guarantee better outcomes (NIH ODS). |
| >50 ng/mL | Review total intake and avoid escalation. |
Independent research, funding, and conflict review
Research funding at a glance
23 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Evidence relied on
| Source | Country | Evidence type | Reported funding/support | Funding/conflict assessment | Evidence limitations | Source role | How used |
|---|---|---|---|---|---|---|---|
| NIH Office of Dietary Supplements | United States | Federal evidence fact sheet | NIH federal source | Government authorship; underlying study finances require separate assessment. | Evidence varies by outcome and population. | Clinical/nutritional evidence summary. | RDA, UL, toxicity, interactions and status interpretation. |
| National Academies DRI report | United States | Consensus dietary-reference report | Government contracts listed in original report front matter. | Government-supported; committee and underlying-study financial chain not fully traced. | Population dietary references are not disease-specific dosing protocols. | Dietary-reference assessment. | Calcium/vitamin D interdependence and UL context. |
| Tripkovic D2/D3 meta-analysis | United Kingdom | 2012 systematic review/meta-analysis | BBSRC DRINC BB/I006192/1. Public/food-drink industry cofinanced programme. | No COI declared; programme and underlying trial support are separate. | Small heterogeneous biomarker trials; pooled daily comparison nonsignificant. | Comparative status-marker synthesis. | D2/D3 status response, not superior clinical outcomes. |
| Calcifediol versus D3 trial | Spain / Italy | Randomized monthly-regimen trial | Faes Farma and Bruno Farmaceutici. | Employee and consultancy/research/lecture ties disclosed. | Laboratory target in postmenopausal women; not fracture superiority. | Formulation/regimen comparison. | Marker speed in the actual studied regimens. |
| Liposomal D3 experiment | Poland | Single-dose healthy-adult crossover plus formulation work | University/National Centre support; commercial production/testing involvement. | Two Lipid Systems partners and two employees. | Early marker response; no clinical indication or cost advantage established. | Formulation investigation. | Experimental status response only. |
| VITAL | United States | Large randomized trial | NIH; donated agents/placebos/packaging and free Quest assays. | Buring spouse Pharmavite board relationship in VITAL disclosures; null results do not remove ties. | Mostly replete older adults; secondary/subgroup analyses require caution. | Primary cancer/CV prevention trial. | Null primary cancer and cardiovascular endpoints. |
| 2017 BMJ review and 2025 update (2017 original; 2025 original) | United Kingdom / international trials | IPD review and later aggregate update | 2017 NIHR HTA; 2025 no external study funding. | 2025 outside supplement/pharmaceutical ties disclosed; included-trial finances not all traced. | 2025 primary overall result nonsignificant; subgroup interactions not established. | Respiratory-infection evidence synthesis. | Historical signal versus updated uncertainty. |
| D2d diabetes trial | United States | Randomized prevention trial | NIDDK/NIH ODS, ADA; capsules purchased from an unrelated firm. | Separate individual disclosure forms and ultimate ADA finances not fully reviewed. | Nonsignificant individual trial; selected current guidance uses wider evidence. | Prediabetes prevention trial. | Individual null result with 2024 conditional guideline context. |
| Drug-vitamin D interaction review | United States | Systematic review | NCI trainee and St Catherine University faculty support in author-institution disclosure record. | Complete COI and included-study finance not verified. | Most clinical studies weak; mechanism does not predict a uniform status change. | Interaction/safety synthesis. | Medicine-specific assessment and monitoring. |
| VITAL-DEP | United States | Randomized prevention trial | NIH plus donated products/packaging and free Quest assays. | Commercial and spouse advisory-board ties disclosed. | Older-adult prevention; not depression/anxiety treatment. | Mood prevention trial. | Null depression/mood prevention. |
| 2014 mortality review | Denmark / Serbia | Systematic review | Copenhagen Trial Unit and Serbian Ministry of Science. | No interests known; includes many industry-supported trials. | Search through 2012; attrition/reporting bias and old evidence. | Mortality synthesis. | Historical small mortality estimate with limitations. |
| 2021 COVID treatment review | Germany | Systematic review | Cologne institutional and German BMBF CEOsys support. | Public institutional grants disclosed. | Small heterogeneous trials; prevention excluded. | COVID treatment synthesis. | Uncertain treatment effects. |
| 2025 deficient-COVID review | China | Meta-analysis | Hunan education/health and university programme grants. | No COI declared; individual trial finances not all traced. | Variable deficiency definitions; mortality not robust. | COVID treatment synthesis. | Uncertain mortality signal and no clear ICU/ventilation benefit. |
| 2017 daily D2/D3 trial | United Kingdom | Randomized fortification trial | BBSRC DRINC; commercial manufacture/nutrient preparation. | Lanham-New D3Tex directorship/patent ties. | Healthy women, winter marker response; supply terms unstated. | Daily formulation comparison. | D3 status advantage in this trial. |
| 2013 D2/D3 trial | Germany | Randomized volunteer trial | German BMBF 0315668A; Zein-Pharma manufactured capsules. | No COI declared; purchase/donation terms unknown. | Short winter marker study, mainly completer analysis. | D2/D3 biomarker comparison. | D2 component rise and D3 component fall. |
| Calcifediol narrative review | Italy | Narrative review | No external funding; FIRMO secretarial assistance. | No COI declared; prior pharma ties of a coauthor appear in the 2021 trial. | Absorption estimates and clinical rationale are not outcome superiority. | Form/clinical-context overview. | Clinician-directed calcifediol context. |
| Vitamin K+D meta-analysis | China | Meta-analysis; abstract accessed | Full original funding/COI unavailable. | Independence unknown. | Full methods not recovered; biomarker outcomes do not prove fewer fractures/CV events. | Bone-marker synthesis. | Qualify routine K2 claims. |
| 2014 India narrative review | United States; review concerns India | Narrative review | Explicit article funding not identified. | Gupta affiliated Rockwell Medical and Charak Foundation; review declares no COI. | Historical protocols and narrative estimates, not current clinical guidance. | India deficiency overview. | Sunlight barriers and historic oral regimens. |
| 2024 older-adult fracture meta-analysis | Brazil / United States affiliations | Meta-analysis | Explicit review funding not identified. | No competing interests declared; included-trial finance not all traced. | Mostly intermittent regimens; no direct daily-versus-bolus comparison; sensitivity limitations. | Fracture synthesis. | Scope caution in older healthy adults. |
| 2018 toxicity review | International authors | Clinical narrative review | Explicit article funding not identified. | No COI declared; complete financial history unverified. | Toxicity prevalence unknown; serum marker depends on cause. | Clinical toxicity overview. | Symptoms and nutritional versus active-form toxicity. |
| IV K2/warfarin model | Japan | Retrospective PK/PD model | Funding none. | No COI declared; procurement terms unstated. | 20–70 mg intravenous K2; not oral microgram MK-7 dosing. | Anticoagulation model. | Route-qualified model only; retail caution uses NIH guidance. |
| 2013 ESCEO consensus | European/international authors | Historical expert guidance | Article not funded; ESCEO supported meeting. | Extensive pharmaceutical/food relationships disclosed. | Old bone-health guidance; society ultimate backing untraced. | Osteoporosis-focused consensus. | Historical dose advice, separated from current prevention guidance. |
| 2024 Endocrine Society guideline | International panel | GRADE prevention guideline | Endocrine Society sole guideline funder. | Managed investigator/consulting/equity ties include vitamin D/pharmaceutical companies. | Conditional recommendations and population boundaries; society ultimate donors untraced. | Prevention guidance. | Testing/dosing context and high-risk-prediabetes exception. |
Evidence excluded or downgraded
| Evidence | Why downgraded |
|---|---|
| Commercial laboratory screening pages | Test-sales information is not a substitute for clinical screening guidance. Assess recommendations against actual guideline populations and disclosed commercial interests. |
| Supplement-brand D3+K2 and liposomal marketing | Product pages often cite mechanisms without hard outcomes and may use affiliate or direct sales incentives. |
| Observational low vitamin D studies | Low vitamin D can be a marker of illness, obesity, inflammation, indoor lifestyle, or low activity; RCTs are weighted more heavily for benefit claims. |
| High-dose injection/sachet anecdotes | Can correct labs but do not establish better clinical outcomes and may increase risk when used as unsupervised bolus therapy. |
Related research
For deeper, evidence-graded context on the conditions vitamin D is most often used for, see Pure City Research's condition guides:
- Type 2 diabetes: prevention and management guide
- Stress, anxiety & depression: prevention and management guide
Frequently Asked Questions
Is vitamin D3 better than vitamin D2?
For raising serum 25(OH)D, D3 generally outperforms D2, especially with bolus dosing. The 2012 pooled daily-dose difference was nonsignificant, while a later daily winter trial in women favoured D3 (2012 review; daily trial). Both are nutritional options; a larger blood-marker response does not guarantee superior clinical outcomes.
What is the safest daily dose of vitamin D?
For adults, recommended total intake is 600 IU/day through age 70 and 800 IU/day thereafter; the chronic UL is 4,000 IU/day (NIH ODS). Neither figure defines the safest dose for every patient. Treatment depends on diet, medicines and medical conditions; routine testing is not recommended for otherwise healthy adults, and an established deficiency needs individual management (2024 guideline).
Can Indians rely on sunlight alone for vitamin D?
Not always: the 2014 India review describes clothing, indoor living and social barriers that can limit sunlight-derived vitamin D (India review). Food, fortification and appropriately selected supplementation can meet needs; deliberate extra UV exposure carries skin risks, and risk factors alone do not establish a need for routine blood tests (NIH ODS, 2024 guideline).
Should vitamin D be taken with K2?
An eight-trial meta-analysis reported BMD and osteocalcin-marker changes, but its accessible abstract does not establish that added K2 prevents fractures or cardiovascular disease (K+D review). Routine K2 is not established as necessary for everyone taking D3. People using warfarin or related vitamin K antagonists should keep vitamin K intake consistent and seek anticoagulation advice before D3+K2 (NIH vitamin K guidance). The cited older K2 model used large intravenous doses, not retail oral MK-7 (IV K2 study).
Does vitamin D help depression or anxiety?
Large prevention evidence does not support vitamin D3 as a depression-prevention supplement: VITAL-DEP found no significant reduction in depression or clinically relevant depressive symptoms with 2,000 IU/day D3 (VITAL-DEP). Correcting a deficiency is still reasonable for general health, but vitamin D should not replace mental-health treatment.
Does vitamin D prevent colds or respiratory infections?
A reliable prevention benefit has not been established. The larger 2025 update found no statistically significant overall protection, and the earlier profound-deficiency benefit was not confirmed. Daily-dose subgroup findings remain uncertain (2025 ARI update).
Can vitamin D cause kidney stones?
Vitamin D alone at normal doses is less clearly linked to stones, but combined calcium plus vitamin D increased kidney stone risk in large evidence reviews (NIH Office of Dietary Supplements, USPSTF evidence review). People with prior stones should avoid high-dose vitamin D plus calcium unless monitored.
Is vitamin D useful for COVID-19?
Correct deficiency for general health, but vitamin D is not a proven COVID-19 treatment. Cochrane found insufficient and very uncertain evidence, while a later deficient-patient meta-analysis reported a possible but non-robust mortality signal and no clear benefit for ICU admission, ventilation, or hospital stay (Cochrane PubMed, 2025 meta-analysis).
Sources
- NIH Office of Dietary Supplements. Vitamin D — Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- National Academies / Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. https://www.nationalacademies.org/read/13050/chapter/7
- National Academies / Institute of Medicine. Tolerable Upper Intake Levels: Calcium and Vitamin D. https://www.ncbi.nlm.nih.gov/books/NBK56058/
- Tripkovic L, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status. https://pubmed.ncbi.nlm.nih.gov/22552031/
- Tripkovic L, et al. Daily supplementation with 15 μg vitamin D2 compared with vitamin D3 in South Asian and White European women. https://pubmed.ncbi.nlm.nih.gov/28679555/
- Lehmann U, et al. Bioavailability of vitamin D2 and D3 in healthy volunteers. https://pubmed.ncbi.nlm.nih.gov/24001747/
- Pérez-Castrillón JL, et al. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women. https://pubmed.ncbi.nlm.nih.gov/34101900/
- Donati S, Marini F, Giusti F, Palmini G, Aurilia C, Falsetti I, Iantomasi T, Brandi ML. Calcifediol: Why, When, How Much? 2023. Research record
- Avenell A, et al. Cochrane: Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. https://www.cochrane.org/evidence/CD000227_vitamin-d-and-related-vitamin-d-compounds-preventing-fractures-resulting-osteoporosis-older-people
- Kahwati LC, et al. USPSTF evidence review: Vitamin D, Calcium, or Combined Supplementation for Primary Prevention of Fractures. https://pubmed.ncbi.nlm.nih.gov/29677308/
- Manson JE, et al. VITAL: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. https://pubmed.ncbi.nlm.nih.gov/30415629/
- VITAL full text with funding disclosures. https://pmc.ncbi.nlm.nih.gov/articles/PMC6425757/
- Okereke OI, et al. VITAL-DEP: Vitamin D3 and depression prevention. https://pubmed.ncbi.nlm.nih.gov/32749491/
- Martineau AR, et al. Vitamin D supplementation to prevent acute respiratory tract infections. BMJ. 2017;356:i6583. Historical IPD review. BMJ; Jolliffe DA, et al. Updated systematic review/meta-analysis. Lancet Diabetes Endocrinol. 2025;13:307–320. 2025 ARI update.
- Pittas AG, et al. D2d: Vitamin D Supplementation and Prevention of Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/31173679/
- Cochrane. Vitamin D supplementation for prevention of mortality in adults. https://www.cochrane.org/evidence/CD007470_vitamin-d-supplementation-prevention-mortality-adults
- Stroehlein JK, et al. Cochrane living review: Vitamin D supplementation for treatment of COVID-19. https://pubmed.ncbi.nlm.nih.gov/34029377/
- 2025 meta-analysis: Vitamin D supplementation for managing COVID-19 in patients with vitamin D deficiency. https://pubmed.ncbi.nlm.nih.gov/40139702/
- Robien K, et al. Drug-vitamin D interactions: systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC5623087/
- Marcinowska-Suchowierska E, et al. Vitamin D Toxicity — A Clinical Perspective. https://pmc.ncbi.nlm.nih.gov/articles/PMC6158375/
- G R, Gupta A. Vitamin D deficiency in India: prevalence, causalities and interventions. 2014. Full text
- Jeyakumar A, et al. Vitamin D deficiency among adolescent girls in selected Indian states. https://pubmed.ncbi.nlm.nih.gov/30304971/
- Food Safety and Standards Authority of India. Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food Regulations, 2016: compendium, Version I, 29 September 2021. Historical version; consult current FSSAI notices for subsequent directions.
- Demay MB, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. 2024. Official recommendations.
- NIH ODS. Vitamin K — Health Professional Fact Sheet: anticoagulant interactions. Official guidance.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
